Sean M. Healey & AMG Center for ALS Announces the Names of 54 Selected Sites for the HEALEY ALS Platform Trial

The Sean M. Healey & AMG Center at Massachusetts General Hospital, in collaboration with the Northeast ALS Consortium (NEALS), is launching the first platform trial for amyotrophic lateral sclerosis (ALS). The goals of this groundbreaking project are to greatly accelerate the timelines towards effective ALS treatments and provide greater trial access for all those affected by this disease.

The HEALEY ALS Platform Trial is a collaborative effort and enrollment in the trial will be available at several sites across the U.S. to bring the trial close to people who want to participate. All sites are part of the NEALS Consortium. See below for a list of participating sites.

The Healey Center at Mass General is working closely with these sites to finalize contracting in the coming weeks and the final list of participating sites will be based on contract execution. Contact information for investigators and staff at each site will become available prior to trial start in early 2020.

For more information, please email healeycenterforals@mgh.harvard.edu.

List of Participating Sites

Site

State

Barrow Neurological Institute

Arizona

Forbes Norris MDA/ALS Research Center, California Pacific Medical Center

California

University of California, Irvine

California

Cedars-Sinai Medical Center

California

Loma Linda University Health

California

University of Colorado

Colorado

Hospital for Special Care

Connecticut

Phil Smith Neuroscience Institute at Holy Cross Hospital

Florida

Mayo Clinic Florida

Florida

University of Florida

Florida

University of Miami

Florida

University of South Florida

Florida

Emory University

Georgia

University of Chicago

Illinois

Northwestern University

Illinois

University of Iowa Hospitals and Clinics

Iowa

University of Kansas Medical Center

Kansas

University of Kentucky

Kentucky

Ochsner Health Systems

Louisiana

John Hopkins University

Maryland

University of Maryland

Maryland

Beth Israel Deaconess Medical Center

Massachusetts

Massachusetts General Hospital

Massachusetts

University of Massachusetts Medical School

Massachusetts

Henry Ford Health System

Michigan

University of Michigan

Michigan

Spectrum Health

Michigan

Mayo Clinic Rochester

Minnesota

University of Minnesota/Twin Cities ALS Research Consortium

Minnesota

University of Missouri Health Care

Missouri

Saint Louis University

Missouri

Washington University School of Medicine

Missouri

University of Nebraska Medical Center

Nebraska

Neurology Associates, P.C./Somnos Clinical Research

Nebraska

Dartmouth-Hitchcock Medical Center

New Hampshire

Columbia University

New York

SUNY Upstate

New York

Duke University

North Carolina

Wake Forest University Health Sciences

North Carolina

The Ohio State University

Ohio

Providence Brain and Spine Institute ALS Center

Oregon

University of Pennsylvania

Pennsylvania

Lewis Katz School of Medicine at Temple University

Pennsylvania

Jefferson Weinberg ALS Center, Thomas Jefferson University

Pennsylvania

Penn State Hershey

Pennsylvania

Medical University of South Carolina

South Carolina

Vanderbilt University Medical Center

Tennessee

Wesley Neurology Clinic

Tennessee

University of Texas Health Science Center at San Antonio

Texas

Houston Methodist

Texas

Texas Neurology

Texas

University of Virginia

Virginia

University of Washington

Washington

Medical College of Wisconsin

Wisconsin

HEALEY ALS Platform Trial Indirect Cost Policy

In executing the Master Clinical Trial Agreement (MCTA) to participate in the HEALEY ALS Platform Trial, Sites agree they will be paid indirect costs (IDC) at the rate at which the originating funding organization reimburses MGH. For payments made from internal MGH philanthropic funds, the IDC will be capped at 15% of total direct costs.